Faculty of Pharmacy Seminar Series
20 April 2012
Harnessing the anti-inflammatory power of the MAPK-deactivator MKP-1 in asthma and airway remodelling.
Asthma is a treatable health condition and we have a number of effective drug treatments to tackle acute asthmatic attacks. With good asthma management, asthmatics can lead normal active lives. But, there are still a number of unanswered questions.
We now know that the airways of asthmatics can become 'thickened' or remodelled over time. The consequence of uncontrolled asthma is that permanent changes in the airways can occur and unfortunately, these cannot be completely reversed with current treatments. As development of remodelled airways is correlated with deterioration of lung function, we urgently require therapies that reduce and reverse structural changes in remodelled airways. Thus, the challenge for asthma treatment today is to identify alternative anti-inflammatory strategies with reduced unwanted effects. In order to aid the future design of efficient anti-inflammatory strategies, we need a greater understanding of the molecular mechanism/s underlying inflammatory pathways.
Our research has shown us that one of the major signalling pathways that drive the development of the pro-remodelled phenotype is the mitogen-activated protein kinases (MAPK) superfamily. Our goal is to harness the power of endogenous anti-inflammatory protein - mitogen-activated protein kinase phosphatase 1 (MKP-1) - in order to switch off MAPKs and ultimately repress airway inflammation. Therefore, enhancing the levels and/or activity of MKP-1 may provide a novel anti-inflammatory strategy in asthma and airway remodelling and our research to date will be presented in this seminar.
Time: 12.00pm - 1.00pm
Contact: Associate Professor Parisa Aslani
Phone: +61 2 9036 6541